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306Induction of Lethal Graft-versus-Host Disease by
Anti-CD137 Monoclonal Antibody in Mice Prone
to Chronic Graft-versus-Host Disease
Wonyoung Kim,1 Juyang Kim,2 Daehee Jung,1 Hyuna Kim,1 Hye-Jung Choi,3
Hong R. Cho,2,4 Byungsuk Kwon1,2Chronic graft-versus-host disease (cGVHD) is an increasingly frequent complication of allogeneic stem cell
transplantation. We previously showed that anti-CD137 monoclonal antibody (mAb) can cure advanced
cGVHD by inducing activation-induced cell death of donor T cells. In this study, we examined whether
administration of anti-CD137 mAb can prevent the development of cGVHD after bone marrow transplan-
tation (BMT) in mice conditioned with total body irradiation (TBI). We used the B10.D2/Balb/c (H-2d) mi-
nor histocompatibility antigen-mismatched model, which reflects clinical and pathological symptoms of
human cGVHD. A single injection of anti-CD137 mAb was administered immediately after BMT. In contrast
to the results obtained from the curing model of cGVHD, anti-CD137 given simultaneously with BMT re-
sulted in lethal GVHD. Histopathologic evaluation revealed inflammation and damage of target organs
from acute GVHD (aGVHD) in anti-CD137-treated mice. Anti-CD137–induced lethal aGVHD required
host cells, as well as irradiation and mature donor T cells. Apparently, anti-CD137 mAb rapidly induced ac-
tivation of donor T cells and sustained their activation status under the inflammatory condition triggered by
irradiation. When given on day 12 after irradiation and BMT, anti-CD137 mAb could still exacerbate GVHD,
but when given on day 30, it could not. Our data demonstrate that anti-CD137mAb can amplify inflammation
induced by host preconditioning, subsequently resulting in lethal aGVHD; thus, alleviating irradiation-induced
toxicity is critical to allow the use of anti-CD137 mAb as GVHD prophylaxis.
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CD137 is a member of the tumor necrosis factor
(TNF) receptor superfamily that functions mainly as
a strong co-stimulatory molecule for CD81 T cells
[1,2]. Since Mittler et al. [3] demonstrated that in vivo
ligation of CD137 abrogates T cell–dependent anti-
body responses, an explosion of studies have demon-
strated the preventive and/or therapeutic effect of
agonistic anti-CD137 monoclonal antibody (mAb) on
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6/j.bbmt.2008.11.035diseases [4-15]. But despite the impressive preventive/
therapeutic effect of anti-CD137 mAb on spontaneous
or experimentally induced diseases, the underlying
mechanisms remain inconclusively defined. Increasing
evidence suggests that anti-CD137 mAb strongly pro-
motes the activation-induced cell death (AICD) of
antigen-specific T cells (including autoreactive and
pathogenic T cells) [4,9,10,12,15,16], which may or
may not result in CD41 T cell tolerance [3,9,13].
Anti-CD137 mAb also can induce the deletion of au-
toreactive B cells by augmenting the production of in-
terferon (IFN)-g by CD81 T cells [5,7,9]. The
therapeutic effect of anti-CD137 mAb remains intact
or decreases mildly in the absence of CD81 T cells in
various disease models, however [9,13-16].
We previously showed that anti-CD137 mAb
inhibits the induction of chronic graft-versus-host dis-
ease (cGVHD) in the DBA/2/unirradiated (C57BL/
6  DBA/2)F1 (BDF1) mice [9]. Surprisingly, anti-
CD137 mAb has been shown to be highly effective
in reversing already established cGVHD in the
B10.D2/Balb/c (H-2d) minor histocompatibility
antigen-mismatched model of cGVHD [15]. This
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cGVHD, including relatively late onset, skin fibroses,
ulcerations, and alopecia, with increased collagen
deposition [17-20]. Treatment of anti-CD137 mAb
between day 30 and day 60 after disease induction
has markedly reduced the symptoms of cGVHD.
The Fas-mediated AICD of donor CD41 T cells is
required for the therapeutic effect of anti-CD137
mAb on cGVHD. These findings suggest co-stimula-
tion as a possible therapeutic intervention in cGVHD.
Because anti-CD137 mAb strongly induces the AICD
of alloreactive donor T cells in parent/unirradiated
F1 hybrid mice [9], these findings also suggest that
anti-CD137 mAb may be used as GVHD prophylaxis.
In this study, we used the B10.D2/Balb/c
cGVHD model to assess the preventive effect of
anti-CD137 mAb on cGVHD. We found that during
the induction and initial phase of cGVHD, anti-
CD137 mAb induced lethal aGVHD, which was asso-
ciated with increased levels of TNF-a and IFN-g in
the large intestine. Treatment with anti-CD137 mAb
rapidly activated donor CD41 T cells and activated
weakly alloreactive donor CD81 T cells. Overall,
anti-CD137 mAb intensified the inflammation trig-
gered by total body irradiation (TBI) and drove the
disease toward systemic lethal GVHD in mice that
otherwise were prone to cGVHD. Our results suggest
that an inflammatory environment after TBI inhibits
the immunosuppression induced by anti-CD137 mAb.MATERIALS AND METHODS
Mice and Antibodies
Male B10.D2 (H-2d) donor mice were purchased
from Japan Shizoka Institute for Laboratory Animals,
Hamamatsu, Japan. Balb/c recipient mice were pur-
chased from Orient, Seoul, Korea. All mice were age
6 to 8 weeks and were maintained in pathogen-free con-
ditions. Anti-CD137 (3H3) mAb [1] was purified from
ascites. Control rat IgG (Ig) was purchased from
Sigma-Aldrich, St. Louis, MO. The study design was
approved by the institutional Animal Care Committee.Bone Marrow T Cell Depletion
Bone marrow (BM) cells were collected by flushing
femurs and tibias from B10.D2 donor mice into MACS
buffer (1  phosphate-buffered saline [PBS], 5 mM
EDTA, and 3% calf serum). After erythrocyte lysis
in hemolysis buffer (144 mM NH4Cl and 17 mM
Tris-HCl [pH 7.2]), BM cells were incubated with bi-
otinylated anti-CD3 mAb for 20 minutes on ice,
washed once, then incubated with streptavidin-
conjugated microbeads (Miltenyi Biotech, Auburn,
CA) for 20 minutes at 4C. Cells were depleted of
CD31 cells using magnetic-activated cell separation(MACS; Miltenyi Biotech). The remaining CD31 cells
routinely composed\1% of the BM cells. Cells were
resuspended in PBS before transplantation.
CD41 and CD81 T Cell Purification
Single-cell suspensions in PBS were prepared from
the spleens and lymph nodes of normal B10.D2 parental
donors, filtered through a sterile mesh (Falcon; BD Bio-
sciences, San Diego, CA) and washed. After the eryth-
rocytes were lysed in hemolysis buffer, the remaining
cells were resuspended in MACS buffer. CD41 or
CD81 T cells were purified using anti-CD4– or anti-
CD8–conjugated magnetic beads (Miltenyi Biotech).
Positively selected cells routinely contained . 90%
CD41 or CD81 T cells.
Bone Marrow Transplantation
Recipient Balb/c mice received 750 cGy from
a cesium irradiator and were reconstituted with 5 
106 of T cell-depleted BM with or without 1  107
of purified CD41 T cells from B10.D2 donors. In
some experiments, cGVHD was induced by transfer-
ring 5  106 of donor T cell–depleted BM and 6 
106 of purified CD81 T cells or 6  106 total spleen/
lymph node cells. A single i.p. injection of anti-
CD137 mAb or control Ig (200 mg per mouse) was
given at various time points after BM transplantation
(BMT).
cGVHD Clinical Scoring System
cGVHD was evaluated as described previously
[21]. In brief, after BMT, the mice were weighed every
3 days and scored for skin manifestations of GVHD
beginning on day 15. The following scoring system
was used: 0, healthy appearance; 1, skin lesions with
alopecia\ 1 cm2 in area; 2, skin lesions with alopecia
1 to 2 cm2 in area; 3, skin lesions with alopecia . 2
cm2 in area. In addition, the mice were assigned 0.3
point each for skin disease (lesions or scaling) on the
ears, tails, and paws. The minimum score was 0, and
the maximum score was 3.9. Incidence curves repre-
sent all mice that achieved a score of 0.6 or higher
and mean clinical scores were calculated for all mice
used for experiments per group.
Histology
Shaved skins from the interscapular region
(approximately 2 cm2), livers, and colons were fixed
in 10% formalin, embedded in paraffin, sectioned,
slide-mounted, and stained with H & E or Masson’s
trichrome.
Pathological Scoring of GVHD
Formalin-fixed livers and distal colons were
embedded in paraffin, and 5-mm-thick sections were
stained with H & E for histological examination. Slides
308 Biol Blood Marrow Transplant 15:306-314, 2009W. Kim et al.were coded and examined in a blinded fashion by a sin-
gle investigator (H.-J.C.), using a semiquantitative sys-
tem for abnormalities known to be associated with
GVHD [22,23].
Reverse-Transcriptase Polymerase Chain
Reaction
RNA was isolated from skins and colons using TRI-
zol reagent (Invitrogen, Carlsbad, CA). Subsequently,
cDNA was synthesized with the M-MLV reverse tran-
scriptase (RT; Invitrogen) for polymerase chain reaction
(PCR), according to the manufacturer’s instructions.
The following primers were used: glyceraldehyde-3-
phosphate dehydrogenase (GAPDH): forward primer,
5´-AGGGCTGCCTTCTCTTGTGAC-3´; reverse
primer, 5´- TGGGTAGAATCATACTGGAACAT
GTAG-3´; IFN-g: forward primer, 5´- CTTCTTCA
GCAACAGCAAGGCGAAAA-3´; reverse primer, 5´-
CCCCCAGATACAACCCCGCAATCA-3´; TNF-a:
forward primer, 5´- AAATGGGCTTTCCGAATTCA
-3´; reverse primer, 5´- CAGGGAAGAATCTG-
GAAAGGT -3´. Amplified DNA was isolated using
1.2% agarose gel, and the density of DNA bands was
analyzed using the ImageGel program (provided by
National Institutes of Mental Health).
Statistical Analysis
Student’s t-test was used to determine the statisti-
cal significance of differences between experimental
groups. Error bars represent standard error of the
mean. Two nonparametric analyses were used: log-
rank Mantel-Cox for incidence and survival curves,
and Mann-Whitney for clinical score data.RESULTS
Administration of Anti-CD137 mAb Induces
Lethal aGVHD
Administration of anti-CD137 mAb was adminis-
tered immediately after transfer of donor BM and
CD41 T cells induced significant weight loss, result-
ing in rapid morbidity. Approximately 70% of the
mice died within 17 days after antibody treatment
(Figure 1A and B), as reported previously [15]. These
results, in concert with other disease symptoms (e.g.,
severe diarrhea, hunched back, ruffled fur texture),
suggest that anti-CD137 mAb might induce more
severe GVHD, including the aGVHD phenotype (sys-
temic or intestinal GVHD) in mice that are genetically
prone to cGVHD. Indeed, histopathologic analysis
revealed crypt apoptosis and inflammation with ulcer-
ation (erosion of the epithelial layer), indicating colitis
7 days after the transfer of donor cells and anti-CD137
treatment. Pathological scores for colons and livers are
summarized in Figure 1C and D.Because anti-CD137 mAb can completely prevent
cGVHD in the DBA/2/unirradiated BDF1 cGVHD
model [9], a possible explanation for the development
of more severe GVHD in the B10.D2/irradiated
Balb/c cGVHD model is that anti-CD137 mAb may
promote the amplification of the ‘‘cytokine storm’’
resulting from irradiation, leading ultimately to a lethal
wasting disease [23]. One study also found that anti-
CD137 mAb exacerbated aGVHD mediated by
CD41 T cells when irradiated recipient mice received
anti-CD137 mAb during the induction phase of the dis-
ease [24]. Consistent with our hypothesis, we noted an
up-regulated expression pattern of IFN-g and TNF-
a mRNAs in the large intestine of anti-CD137–treated
mice (Figure 1E and F). Because potentially cytotoxic
donor CD81 T cells are excluded from the donor
cell population in our cGVHD model, the amplified
cytokine storm may contribute mainly to the intestinal
damage.
Anti-CD137 mAb Exacerbates GVHD Induced
by Donor CD41 and CD81 T Cells
To examine the effects of anti-CD137 mAb on
cGVHD induced by donor CD41 and CD81 T cells,
we introduced total B10.D2 spleen/lymph node cells
into irradiated Balb/c mice. Similar to mice that
received donor CD41 T cells, anti-CD137 mAb in-
duced severe loss of body weight in mice that received
both CD41 and CD81 T cells (Figure 2A); however,
there was no significant difference in the severity and
penetrance of cutaneous GVHD and survival rate be-
tween the anti-CD137–treated and control Ig-treated
mice (Figure 2B-D). Interestingly, transfer of both do-
nor CD41 and CD81T cells resulted in lethal GVHD
in most of the control Ig-treated host mice (even
though these mice did not experience significant
weight loss) compared with the anti-CD137–treated
host mice (Figure 2A). Taken together, our results sug-
gest that even though donor CD81T cells alone are not
able to induce cGVHD [15 and 25; also see Figure 3],
donor CD81 T cells may contribute to the develop-
ment of cGVHD in the presence of donor CD41 T
cells, as has been suggested by other studies [26].
Donor CD81 T Cells Activated by Anti-CD137
mAb Induce GVHD
We next investigated the immunomodulatory
effect of anti-CD137 mAb on donor B10.D2 CD81
T cells when transferred into Balb/c recipients. Not
surprisingly, administration of anti-CD137 mAb led
to significant loss of body weight compared with con-
trol Ig (Figure 3A). The survival rate did not differ sig-
nificantly between the anti-CD137–treated mice and
the control Ig-treated mice, however (Figure 3B). His-
topathologic analysis demonstrated more severe
inflammation and tissue destruction in the colons of
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Figure 1. Anti-CD137mAb induces aGVHDwhen given during the induction phase of cGVHD. Balb/c recipient mice were irradiated with 750 cGy and
reconstituted with 5  106 BM cells and 1  107 purified CD41 T cells from B10.D2 donor mice. Anti-CD137 mAb (200 mg per mouse) was admin-
istered immediately after transfer of donor cells (n5 10 per group). A, Loss of bodyweight. *P\.05 between the 2 groups at the indicated time points. B,
Percent survival. **P\.01 between the 2 groups. C and D, Pathological scores of colons and livers (n 5 7 to 10 per group). Colons and livers were
harvested 7 days after disease induction, and H & E–stained colon (C) and liver (D) sections were scored for pathology. *P\.05 between the 2 groups.
E and F, Expression of IFN-g (G) and TNF-a (H) in colons at various times after disease induction and antibody treatment (n5 3 to 5 per group). RNA
was extracted from colons, and RT-PCR was performed. Expression levels of cytokines were normalized to those of GAPDH. **P\.01 and ***P\.001
between the 2 groups at the indicated times. The results are representative of more than 3 independent experiments.
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of the mice that survived (8 of 10 mice) exhibited
clearly visible and histopathologic cutaneous GVHD,
although the disease proceeded more slowly in these
mice compared with mice with cGVHD induced by
donor CD41 T cells (Figure 3C-E). Our findings sug-
gest that anti-CD137 mAb may activate alloreactive
donor CD81 T cells that do not have the ability to
induce clinical GVHD without help from donor
CD41 T cells, resulting in the induction of intestinal
and cutaneous GVHD.CD137-Expressing Host Cells Contribute to
Acute Lethal Toxicity of Anti-CD137 mAb
CD137 is expressed on various non–T cells, in-
cluding natural killer (NK) cells [27], dendritic cells[28,29], neutrophils [30], monocytes [31], eosinophils
[32], and mast cells [33]. Thus, anti-CD137 mAb
may possibly increase the lethal effect of cytokine cas-
cades generated by irradiation-primed host cells after
TBI. To investigate this possibility, we induced
cGVHD in wild-type (WT) and CD137-deficient
Balb/c recipients and administered anti-CD137 mAb
or control Ig immediately after donor cell transfer.
Compared with the WT mice, the CD137-defi-
cient mice were significantly more resistant to
GVHD after donor cell transfer in all of the measures
evaluated, including weight loss, survival rate, and cu-
taneous GVHD score (Figure 4). Nonetheless,
administration of anti-CD137 mAb resulted in severe
GVHD in these CD137-deficient mice (Figure 4).
Our results indicate that administration of anti-
CD137 mAb greatly contributes to lethal GVHD by
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Figure 2. Anti-CD137 mAb exacerbates cGVHD induced by donor CD41 and CD81 T cells. Balb/c recipient mice were irradiated with 750 cGy and
reconstituted with 5 106 BM and 6  106 spleen/lymph node cells isolated from B10.D2 donor mice. Immediately thereafter, 200 mg of anti-CD137
mAb or control Ig was injected. A, Changes in body weight. **P\.01 and ***P\.001 between the 2 groups at the indicated time points (n5 9 or 10 per
group). B, Percent survival. C, Mean clinical scores. D, Incidence of cGVHD. Experiments were repeated more than 3 times.
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situations in which anti-CD137 mAb does not amplify
a cytokine storm generated by irradiation-primed host
cells. But considering that anti-CD137 mAb induced
earlier and more rapid mortality in the WT recipi-
ents, it seems that CD137-expressing host cells are
required for acute lethal toxicity of anti-CD137
mAb (Figure 4B). Interestingly, anti-CD137–treated
CD137-deficient host mice that survived lethal
GVHD exhibited more severe cutaneous GVHD.
Taken together, our results suggest that the acute le-
thal toxicity of anti-CD137 results from the interplay
of donor T cells and factors generated by irradia-
tion-primed host cells after engagement of CD137.TheHarmful Influence of Irradiation Is a Critical
Factor Determining the Toxicity of Anti-CD137
mAb
To further examine whether the toxic effect of
anti-CD137 mAb is governed by the cytokine storm
resulting from TBI in our cGVHD model, we
administered anti-CD137 mAb on day 12 and again
on day 30 after disease induction. We hypothesized
that the cytokine storm wanes significantly by day 12
and disappears by day 30 after disease induction.
When administered 12 days after disease induction,
anti-CD137 mAb resulted in more severe weight
loss and earlier appearance of cutaneous GVHD
(Figure 5A and C). The survival rate did not differsignificantly between the control Ig-treated and anti-
CD137–treated mice (Figure 5B). In contrast, admin-
istration of anti-CD137 mAb on day 30 after disease
induction reversed GVHD in the context of weight
loss, survival, and clinical scores (Figure 5D-F), as
reported previously [15]. Overall, our findings suggest
that a cytokine environment formed by irradiation is
critical in determining the toxicity of anti-CD137
mAb in cGVHD.DISCUSSION
cGVHD commonly occurs in patients who
undergo allogeneic stem cell transplantation. Although
the manifestations of cGVHD differ among patients,
common clinical complications include fibrosis and
scleroderma-like changes [34]. cGVHD is mediated
by pathogenic donor T cells generated after alloreac-
tivity to host major or/and minor histocompatibility
antigens or autoantigens [34]. These T cells damage
target tissue directly through various effector mecha-
nisms [34]. Because of the still poorly understood path-
ophysiology of this T cell–mediated syndrome, few
prophylactic and therapeutic approaches have targeted
pathogenic T cells specific for alloantigens. Previous
animal studies by our laboratory have provided evi-
dence that in vivo depletion of pathogenic T cells by
anti-CD 137 mAb can be used to reverse already estab-
lished cGVHD [9,15]; however, anti-CD137 mAb
Figure 3. Anti-CD137mAb activates donor CD81 T cells. Balb/c recipient mice were irradiated with 750 cGy and reconstituted with 5 106 BM and
6  106 CD81 T cells purified from B10.D2 donor mice. Immediately thereafter, 200 mg of anti-CD137 mAb or control Ig was injected. A, Changes in
body weight. *P\.05 between the 2 groups from day 12 onward except day 37 (n5 10 per group). B, Percent survival. C, Mean clinical scores. **P\.01
and ***P\.001 between the 2 groups at the indicated time points. D, Incidence of cGVHD. **P\.01 between the 2 groups. E and F, H & E staining of skin
and colon sections (E) and pathological scores of the colon (F). Samples were harvested on day 58 after disease induction (n5 6 or 7 per group). The
experiments were repeated, and similar data were obtained.
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around the time when mice receive irradiation and
BMT [15, 24]. Thus, insight into the mechanism
underlying anti-CD137 mAb’s toxicity in GVHD is
needed to allow the use of this antibody as GVHD pro-
phylaxis. Our findings suggest that the cytokine milieu
formed after TBI guides the effects of anti-CD137
mAb in 2 directions. First, anti-CD137 mAb seems to
amplify the cytokine storm triggered by irradiation,
mainly through irradiation-resistant host cells. Thesubsequently amplified cytokine storm becomes a
critical component that induces acute lethal toxicity
(Figure 1). Second, cytokines produced after TBI aug-
ment the activation of donor T cells by anti-CD137
mAb. Even though anti-CD137 mAb is not sufficient
to produce a lethal toxic effect when mice receive T
cell–depleted BM alone [15], the administration of
anti-CD137 mAb produces acute mortality in the pres-
ence of donor T cells (Figure 4). In contrast, without
the amplification process of the cytokine storm (i.e.,
Figure 4. Inhibition of acute mortality induced by anti-CD137 mAb in
CD137-deficient mice. WTand CD137-deficient Balb/c mice were irra-
diated with 750 cGy and reconstituted with 5  106 BM and 6  106
spleen/lymph node cells isolated from B10.D2 donor mice. Immediately
thereafter, 200 mg of anti-CD137 mAb or control Ig was injected. A,
Changes in body weight. *P\.05, **P\.01, and ***P\.001 between
control Ig-treated and anti-CD137-treated groups at the indicated
time points (n 510 per group). B, Percent survival. *P\ .05 between
the indicated groups. C, Mean clinical scores. ***P\.001 between the
control Ig-treated and antiCD137-treated groups at the indicated time
points.
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CD137 mAb have slower kinetics of mortality (Fig-
ure 4). Note that in this case, donor T cells activated
by anti-CD137 mAb induced lethal GVHD in most
of the host mice. Considering that anti-CD137 mAb
promotes the AICD of donor T cells in the parent/
unirraidated F1 GVHD models (i.e., in the absence
of acute inflammation) [15; our unpublished data],
the formation of a cytokine environment after irradia-tion is critical in preventing anti-CD137 mAb from
triggering the AICD of donor T cells. Thus, down-reg-
ulation of the cytokine storm should be considered, to
allow the use of anti-CD137 mAb as GVHD prophy-
laxis.
Accumulating evidence suggests that in vivo dele-
tion of T cells by anti-CD137 mAb occurs through
AICD in various disease models [4,9,10,12,15,16].
The Fas death pathway is required for AICD induced
by anti-CD 137 mAb [15,16]. Zhang et al. [16] dem-
onstrated that production of IL-10 and TNF-a by
anti-CD137 mAb results in the up-regulation of Fas
on T cells during acute viral infection. On one
hand, because anti-CD137 mAb seems to up-regulate
TNF-a after TBI (Figure 1), irradiation must pro-
mote the production of factor(s) antagonizing the
AICD of donor T cells induced by anti-CD137
mAb. Our laboratory is currently searching for these
factors. On the other hand, because alloreactive T
cells express CD137 [35], it might be possible to
remove alloreactive T cells by stimulating them with
anti-CD137 mAb together with interleukin-10 and
TNF-a in an in vitro mixed leukocyte reaction
(MLR). This possibility is also under investigation
in our laboratory.
Alloreactive T cells respond in a complex manner
when transferred into an allogenic environment. After
transfer, massive alloreactive T cell expansion occurs,
along with extensive T cell anergy, apoptosis, and rep-
ertoire selection [36]. It is not uncommon for donor
CD81 T cells to become unresponsive to alloantigens
after being transferred into the host in cGVHD
models. Most donor CD81 T cells experience a short
burst of expansion, followed by AICD and the devel-
opment of anergy in the residual population in
cGVHD models, including the model used in the pres-
ent study [37-46]. Because a high dose of donor CD81
T cells can induce lethal GVHD only in the presence
of donor CD41 T cells, as found in the present study
(Figure 2), donor CD81 T cells apparently would
fall into anergy without the help of CD41 T cells
[15,39]. Consistent with our findings (Figure 3), a pre-
vious study found that in vivo engagement of CD137
prevents anergy of alloreactive CD81 T cells [47].
Taken together, these findings suggest that co-
stimulatory signaling through CD137 is more effective
in breaking alloreactive CD81 T cell anergy and their
subsequent activation when help is provided from
CD41 T cells.
In conclusion, our findings clearly demonstrate
that anti-CD137 mAb induces an acute type of lethal
GVHD in mice that are genetically prone to cGVHD.
This is because irradiation and anti-CD137 mAb
mutually amplify their respective effects, acute inflam-
mation and T cell activation. Consequently, reducing
the toxicity of conditioning is important to allow the
use of anti-CD137 mAb as GVHD prophylaxis.
Figure 5. The toxic effect of anti-CD137 mAb is time-dependent. Balb/c recipient mice were irradiated with 750 cGy and reconstituted with 5  106
BM and 6 106 spleen/lymph node cells isolated from B10.D2 donor mice. Anti-CD137 mAb or control Ig was injected 12 (A-C) or 30 (D-F) days after
disease induction. A and D, Changes in body weight. *P\.05 between the 2 groups at the indicated time points (n 5 10 per group). B and E, Percent
survival. *P\.05 between the 2 groups (n5 10 per group). C and F, Mean clinical scores. *P\.05 and **P\.01 between the 2 groups at the indicated
time points (n 5 10 per group).
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